IDEC-114 IDEC

Current Opinion in Investigational Drugs

Volumn 2, Issue 5, 2001, Pages 635-638

  Schopf, R E ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD28 ANTIGEN; CYCLOSPORIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GALIXIMAB; IMMUNOGLOBULIN G; RECOMBINANT ANTIBODY; TACROLIMUS; UNCLASSIFIED DRUG;

ASTHENIA; AUTOIMMUNE DISEASE; BINDING KINETICS; CELL SURFACE; CLINICAL TRIAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; GRAFT REJECTION; HEADACHE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE RESPONSE; IMMUNOMODULATION; INFLAMMATION; LONG TERM CARE; NAUSEA; PHARMACEUTICAL ENGINEERING; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; STRUCTURE ACTIVITY RELATION; SYSTEMIC LUPUS ERYTHEMATOSUS; VERTIGO;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; CLINICAL TRIALS; HUMANS; PSORIASIS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0034984194     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Effects of cyclosporin A, FK 506, and mycalamide A on the activation of murine CD4+ T cells by the murine B7 antigen
2. IDEC Pharmaceuticals - Corporate backgrounder
3. B7-1 and B7-2 costimulatory molecules activate differentially the Th1-Th2 developmental pathways: Application to autoimmune disease therapy
4. Expression and functional analysis of murine B7 delineated by a novel monoclonal antibody
5. Professional presentation of antigen by activated human T cells
6. mAb 104, a new monoclonal antibody, recognizes the B7 antigen that is expressed on activated B cells and HTLV-1-transformed T cells
7. IDEC licenses protein design's humanisation patent
8. IDEC Pharmaceuticals receives notice of allowance on additional patents covering PRIMATIZED antibody technology
9. IDEC Pharmaceuticals reports third quarter 1998 results
10. IDEC Pharmaceuticals initiates phase I study with primatized antibody, IDEC-114, in patients with psoriasis
11. IDEC Pharmaceuticals begins phase I/II study in psoriasis with PRIMATIZED antibody, IDEC-114
12. IDEC Pharmaceuticals announced results of phase I study of IDEC-114 antibody in psoriasis
13. Results of a single-dose, dose-escalating trial of an anti-B7.1 monoclonal antibody (IDEC-114) in patients with psoriasis
14. Mechanisms of disease: Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases
15. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity
16. T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resitant interleukin 2 gene expression
17. Psoriatic skin-derived dendritic cell function is inhibited by exogenous IL-10. Differential modulation of B7-1 (CD80) and B7-2 (CD86) expression
18. Studies using antigen-presenting cells lacking expression of B 7-1 (CD80) and B7-2 (CD86) show distinct requirements for B7 modecules during priming versus restimulation of Th2 but not Th1 cytokine production
19. Distinct roles for B7-1 (CD80) and B72 (CD86) in the initiation of experimental allergic encephalomyelitis
20. Treatment with anti-tumor necrosis factor α (TNF-α) monoclonal antibody dramaticially decreases the clinical activity of psoriasis lesions
21. Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis
22. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4lg) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells
23. IDEC Pharmaceuticals begins phase II study in psoriasis with its PRIMATIZED antibody, IDEC-114